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INTRODUCTION
At present, the group of genetically determined and 
clinically polymorphic pathological conditions unit-
ed under the term “undiff erentiated connective tissue 
disease” (UCTD) is becoming increasingly important 
in obstetric-gynecological practice. Th is is primarily 
due to its high prevalence - up to 80% among women 
of reproductive age and from 20 to 30% in pregnant 
women (1-3). Secondly, it is associated with compli-
cations of pregnancy and childbirth such as the threat 
of termination of pregnancy at diff erent periods, isth-
mic-cervical insuffi  ciency, gestosis, placental insuffi  -
ciency and chronic intrauterine hypoxia of the fetus, 
premature birth, untimely discharge of amniotic fl uid, 
uteral scar insuffi  ciency, and postpartum hemorrhages 
(4,5).
It has been established that the development of the 
disease is based on mutations of the genes responsible 
for the synthesis/catabolism of the structural proteins 
of the connective tissue and the enzymes involved in 
these processes, the quantitative change in the forma-
tion of the full components of the extracellular matrix, 
and impared fi brillogenesis. Moreover, in recent years, 
there is increasing evidence of the presence of vitamin 
and micronutrient defi ciencies in UCTD. Th e leading 
role in the development of pathology is attributed to 
the defi ciency of Mg and vitamin D. Enhanced degra-
dation of collagen fi bers and, probably, elastin fi bers, 
as well as polysaccharide fi laments of hyaluron (3,6-9) 
seem to be the probable mechanisms of infl uence of 
Mg defi ciency on connective tissue. American scien-
tists in their study confi rmed that a low level of vita-
min D in a pregnant woman’s body contributes to an 
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increase in the frequency of health complications in 
both the mother and the newborn. Children born with 
a vitamin D defi ciency have a lower birth weight. Vita-
min D defi ciency during pregnancy not only disrupts 
the mother’s skeletal system and the formation of the 
fetal skeleton, but also has a clear eff ect on the child’s 
susceptibility to illness immediately aft er birth, as well 
as later. Nevertheless, it is noted that taking vitamin D 
in the form of vitamin complexes or food supplements 
can reduce the risk of possible complications: sponta-
neous abortion, premature birth, pre-eclampsia, and 
fetal growth retardation syndrome (10-14). Vitamin D 
has an integrated eff ect on the structure of the con-
nective tissue: by stimulating the expression of the en-
coding gene of the transforming growth factor-beta, it 
is necessary for cell division and diff erentiation of os-
teocytes, chondrocytes, fi broblasts, and keratinocytes 
(15,16). At the molecular level, the eff ect of vitamin D 
is due to stimulation of prostaglandin production, an 
increase in intracellular pH and water content in the 
membrane, an infl uence on the metabolism of mem-
brane phospholipids, activation of calcium channels, 
an increase in cytosolic and nuclear levels of ionized 
calcium (9,17).
Th us, the objective of this research was to study the 
eff ect of the inclusion of the magnesium and vitamin 
D-containing drug in the medication regimen of preg-
nant women with undiff erentiated connective tissue 
disease on their course of pregnancy, childbirth, the 
state of new mothers and newborns.
SUBJECTS AND METHODS
Th e analysis of the course of pregnancy and the deliv-
ery outcomes of 142 pregnant women with manifesta-
tions of moderate severity undiff erentiated connective 
tissue disease (UCTD) . 
UCTD was diagnosed by the presence of external 
and visceral phenotypic symptoms of connective tis-
sue dysplasia in women (at least 5 out of the above): 
hypermobility of joints, increased skin elasticity, sco-
liosis, congenital dislocation or dysplasia of the hip 
joints, spontaneous pneumothorax, nephroptosis, du-
plication of kidneys and / or urinary tract, increased 
bleeding (nasal and gingival bleeding, as well as heavy 
menstruation), varicose veins of the lower extremities, 
myopia.
To determine the UCTD severity, the criteria by T. Yu. 
Smolnova et al. (2003) were used. According to the au-
thor, there are distinguished: 
• Minor signs (1 point): Asthenic body type or 
insuffi  cient body weight, the absence of stretch 
marks on the skin of the anterior abdominal 
wall in women who had a history of childbirth, 
impaired refraction at the age under 40, muscu-
lar hypotonia and low manometry, fl atfoot, easy 
bruisability, hemorrhagic tendency, hemorrhage 
in the puerperal period, vegetovascular dysfunc-
tions, abnormal heart rhythm and conduction 
(ECG), scoliosis, kyphosis, kyphoscoliosis.
• Large signs (2 points): II-III grade fl at feet, skin 
elastosis, hypermobility of the joints, tenden-
cy to dislocations, sprains of the joint ligaments, 
tendency to allergic conditions and colds, tonsil-
lectomy, varicose disease, hemorrhoids, biliary 
dyskinesia, impaired evacuation, biliary tract dys-
kinesia, disturbed GI evacuation function.
• Severe manifestations and conditions leading to 
surgical interventions or having indications for 
them, as well as changes in anatomical relation-
ships that led to dysfunction of organs (3 points): 
Th e threat of premature birth at 32-35 weeks, 
pregnancy, premature birth, fast and rapid child-
birth in history with hypotonic bleeding or with-
out it at the third stage of labor, prolapse, genita-
lia and hernia in relatives of the fi rst line, hernia, 
splanchnoptosis, varicose veins and hemorrhoids 
(surgical treatment), chronic venous insuffi  cien-
cy with trophic disorders, habitual dislocations 
of the joints or dislocations of more than 2 joints, 
impairments of the motor function of the gastro-
intestinal tract, confi rmed by laboratory methods 
(Re - logical, -scopic), diverticula, dolichosigmoid, 
polyvalent allergy, severe anaphylactic reactions.
Th e total score up to 9 corresponds to minor severity (mi-
nor UCTD); from 10 to 16 - moderate severity (moder-
ate); from 17 and more –severe (frank UCTD).
Th e inclusion criteria were: age from 18 to 44 years 
(young age according to WHO), the presence of at least 
5 phenotypic symptoms of connective tissue dysplasia in 
women, pregnancy on the background of UCTD, sin-
gleton pregnancy, and an informed consent to the ex-
amination.
Th e exclusion criteria were age over 44 years, the pres-
ence of less than 5 symptoms of connective tissue dyspla-
sia, Marfan syndrome, incomplete osteogenesis, severe 
concomitant extragenital pathology that is not consid-
ered in the framework of UCTD; multiple pregnancy, 
refusal to sign an informed consent.
Depending on the patient’s treatment regimen, the pa-
tients were divided into two groups: group 1 (main), 
(n=87) included pregnant women who received 
Magne-B6 (Sanofi , France) from the fi rst to the end of 
the third trimester (12-36 weeks of gestation) in a dose 
of 4 tablets per day (192 mg) continuously. 
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Th e average ages of patients in the groups under study 
were close to each other and amounted to 25.2 ± 1.2 years 
in group 1 and 25.8 ± 1.2 years in group 2, respectively 
(p> 0.05).
Th e second (control) group (n=55), in addition to the 
magnesium drugs, received vitamin D3 (Aquadetrim, 
Medana Pharma, Poland) in a dose of 1000 IU/day 
continuously.
Th e women admitted of or rejected from the proposed 
therapy was completely dependent on the desire of 
patients. Some of them did not agree to take the pro-
posed drugs (magnesium, vitamin D for personal or 
fi nancial reasons).
Pregnant women were observed from the fi rst to the 
end of the third trimester of pregnancy, in labor and 
the early postpartum period. Examination of pregnant 
women and women in labor was carried out according 
to a single scheme, including the study of general and 
obstetric and gynecological history, the characteristics 
of the course of this pregnancy, childbirth, the post-
partum period of the newborn.
Analysis of the obtained data was based on the princi-
ples of evidence-based medicine. Statistical processing 
of the obtained data was carried out with Microsoft  
Excel 2007 and IBM SPSS Statistics 19 (USA). Expect-
ed arithmetic mean and standard error (M±m) were 
calculated. Diff erences between groups were evaluated 
by quantitative parameters using Student’s t-test (p); in 
case of incorrect distribution of compared indicators 
or the number of observations in one of the groups 
less than 30, the Mann–Whitney u-test (pm-u) was 
used. Diff erences between groups by relative values 
were evaluated by the criterion χ2 (рχ2), if one of the 
values was less than 5, the Fisher’s exact method (F) 
was used. Diff erences were considered statistically sig-
nifi cant when the error probability (p) is less than 0.05.
RESULTS
Analysis of the incidence of pregnancy complications 
in women, depending on the treatment regimen, re-
vealed (Table 1) that the group of patients, who re-
ceived combination therapy with the magnesium and 
vitamin D-containing drug, had signifi cantly fewer 
cases of pre-eclampsia (4 (7.3%) cases in the control 
group against 18 (20.7%) - in group 1, p=0.031) and 
fetal growth retardation syndrome (8 (14.5%) cases 
in the control group 2 against 27 (31%) in the main 
group (p=0.026) 
Table 1. 
Th e incidence of pregnancy complications in women with 
UCTD, depending on their treatment regimens
Condition
Group 1 (n=87) Group 2 (n=55)
χ2 p
abs. % abs. %
Threatened abortion, 
first trimester
56 64.4 34 61.8 0.094 0.759
Threatened abortion, 
second trimester
60 69.0 39 70.9 0.060 0.806
Threatened premature 
birth
61 70.1 41 74.5 0.327 0.576
Isthmic-cervical 
insufficiency
36 41.4 27 49.1 0.812 0.368
Preeclampsia 18 20.7 4 7.3 4.633 0, 031*
Anemia of pregnancy 30 34.5 20 36.4 0.052 0.819
Chronic intrauterine 
fetal hypoxia
20 23.0 12 21.8 0.026 0.871
Fetal growth 
retardation
19 21.8 5 9.1 3.899 0.048*
Notes: * reliability - p<0.05, as compared between the groups
Premature labor was observed in 12 (13.8%) women 
of the main group and 8 (14.5%) of the control group 
(p=0.900). Th e analysis of the incidence of complica-
tions during labor in women suff ering from UCTD, 
depending on their treatment regimens, revealed no 
signifi cant diff erences between the groups, just as 
when comparing the incidence of postpartum compli-
cations (Table 2).
Table 2. 
Th e incidence of labor and post-labor complications in 
women with UCTD, depending on their treatment regimens
Condition
Group 1 (n=87) Group 2 (n=55)
Χ2 p
abs. % abs. %
Labor complications 
Untimely discharge of 
amniotic fluid
10 11.5 6 10.9 0.012 0.914
Uterine inertia 10 11.5 4 7.3 0.676 0.411
Discoordinated labor 
activity
8 9.2 6 10.9 0.111 0.739
Acute fetal hypoxia 9 10.3 5 9.1 0.060 0.807
Placental abruption 4 4.6 2 3.6 0.077 0.781
Postpartum complication
Endometritis 33 37.9 17 30.9 0.728 0.393
Hematometra 6 6,9 2 3.6 0.674 0.412
Postoperative 
hematomas
9 10.3 5 9.1 0.060 0.807
Hypotonic bleeding 10 11.5 10 18.2 1.245 0.264
Increased blood loss in 
postpartum period
20 23.0 16 29.1 0.663 0.415
Mild anemia 20 23.0 10 18.2 0.467 0.494
Moderate anemia 11 12,6 7 12.7 0.000 0.988
Severe anemia 13 14,9 11 20.0 0.614 0.433
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Table 3. 
Average anthropometric parameters of newborns of women 
with UCTD depending on their treatment regimen (M±m)
Parameter Group 1 (n=87) Group 2 (n=55) P
Body weight, g 3311.6 ± 544.9 3359.5± 625.5 0.655
Body height, cm 47.3± 4.4 46.6 ±5,0 cm 0.460
Chest circumference, cm 31.4 ± 2.7 32.5 ± 2.9 0.071
Head circumference, cm 32.5 ± 2.3 32.6 ± 2.3 0.801
Table 4. 
Dynamics of assessment of the functional state of the 















Abs. % Abs. % Abs. % Abs. %
8-9 
points
4 4.7 2 3.6 0.781 19 21.8 18 32.7 0.174
6-7 
points
50 57.3 27 49.1 0.329 49 56.4 26 47.3 0.287
4-5 
points
26 29.9 22 40.0 0.215 17 19.5 10 18.2 0.790
1-3 
points
7 8.0 4 7.3 0.867 2 2.3 1 1.8 0.755
Note: p - comparison between groups 1 and 2 in terms of minutes 1 
and 5 
It was revealed that the average values of the anthro-
pometric parameters of newborns at birth did not dif-
fer signifi cantly between the groups (Table 4) and did 
not go beyond the average indicators of the norm.
Th e dynamics of the functional status of newborns 
on the Apgar scale 1 and 5 minutes aft er birth, when 
compared in groups at a specifi c point in time, had sig-
nifi cant and statistically confi rmed diff erences (Table 
4). At the same time, newborns showed a faster adap-
tation to the environment, expressed in an increase in 
the number of newborns with a maximum score: in 
group 2 - 9 times (from 2 (3.6%) children during the 
fi rst minute to 18 (32.7%) children by the fi ft h minute) 
than in group 1 - 4.6 times (from 4 (4.7%) children 
during the fi rst minute to 19 children (21.8%) by the 
fi ft h minute of observation, respectively), p<0.05.
Th e obtained data on adaptation indicators of new-
borns are consistent with the analysis of complications 
of the early neonatal period: children born by mothers 
with UCTD and receiving magnesium and vitamin D 
during pregnancy showed signs of morphofunctional 
immaturity (25.4% against 42.5%) in the main group, 
p = 0.030) and the development of conjugation jaun-
dice (27.3% against 46% in the main group, p=0.019) 
Table 5. 
Th e incidence of complications in the early neonatal period 
in newborns born by mothers with UCTD
Parameter
Group 1 (n=87) Group 2 (n=55)
Χ2 p
abs. % abs. %
Morphofunctional 
immaturity
37 42.5 14 25.4 3.780 0.030*
Conjugation jaundice 40 46.0 15 27.3 5.481 0.019*
Respiratory distress 
syndrome
7 8.0 5 9.1 0.031 0.860
Convulsive disorder 6 6.9 6 10.9 0.632 0.427
Skin hemorrhagic 
syndrome
11 12.6 7 12.7 0.001 0.971
DISCUSSION
Magnesium defi ciency leads to impaired metabolism 
of connective tissue, which is especially important for 
UCTD. Pregnancy itself is a condition accompanied 
by a defi ciency of this macronutrient. Th us, the com-
bination of UCTD and magnesium defi ciency during 
pregnancy, aggravating each other, have an adverse ef-
fect on the course of pregnancy and its outcome (7, 8).
Vitamin D is an important prehormon that is involved 
in many metabolic processes. Vitamin D and 1a-hy-
droxylase receptors are found in the tissues of the re-
productive organs, including the ovaries, uterus, pla-
centa, testicles and pituitary gland, which confi rms its 
role in reproductive health. Th e mechanisms are de-
scribed, through which vitamin D defi ciency in serum 
can increase the risk of pre-eclampsia: it is a powerful 
endocrine suppressor of renin biosynthesis which can 
prevent hypertension through suppression of the re-
ninangiotensin system and proliferation of vascular 
smooth muscle cells, reduce blood insulin, improve 
endothelial-dependent vazodilation and inhibit anti-
coagulant activity. In addition, the active form of vi-
tamin D regulates the transcription and function of 
genes associated with trophoblast invasion, normal 
implantation and angiogenesis (14,16,18). Th e rela-
tionship between the pregnant woman and the fetus 
leads to the fact that the maternal defi ciency of vita-
min D during pregnancy creates a defi cient state in 
the child, beginning with the period of intrauterine 
development. Drug compensation of this condition in 
a pregnant woman reduces the risk of complications 
from both the new mother and the newborn (9,17).
Th us, the obtained results of treatment of pregnant 
women with undiff erentiated connective tissue dis-
ease confi rmed the data on the eff ectiveness of com-
bination therapy with magnesium and vitamin D: 
a lower percentage of preeclampsia (18.2% against 
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34.5% in the control group, p=0.035) and fetal growth 
retardation (14.5% against 31%, respectively, p=0.026) 
were detected. Moreover, analysis of the condition of 
the newborns of these mothers revealed faster physio-
logical adaptation in the early postpartum period (an 
increase in the number of children with Apgar scores 
of 8–9 from 3.6% during the fi rst minute to 32.7% by 
the fi ft h minute against 4.7% and 21.8%, respectively, 
in the control group, p<0.05; they showed signifi cant-
ly less signs of morphofunctional immaturity (25.4% 
against 42.5% in the main group, p=0.030) and the 
development of conjugation jaundice (27.3% against 
46% in the main group, p=0.019).
CONCLUSION
Th us, oral administration of magnesium and vitamin 
D drugs throughout pregnancy compensates for their 
defi ciency in pregnant women with undiff erentiated 
connective tissue disease, which reduces the risk of pre-
eclampsia (18.2% against 34.5% in the control group, 
p=0.035) and fetal growth retardation syndrome (14.5% 
against 31%, respectively, p=0.026). Moreover, analysis 
of the condition of the newborns of these mothers re-
vealed faster physiological adaptation in the early post-
partum period (an increase in the number of children 
with Apgar scores of 8-9 from 3.6% during the fi rst 
minute to 32.7% by the fi ft h minute against 4.7% and 
21.8%, respectively, in the control group, p<0.05; they 
showed signifi cantly less signs of morphofunctional 
immaturity (25.4% against 42.5% in the main group, 
p=0.030) and the development of conjugation jaundice 
(27.3% against 46% in the main group, p=0.019).
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Pozadina: Važnost nediferencirane bolesti vezivnog tkiva (UCTD) u opstetričkoj i ginekološkoj praksi povezana je s viso-
kom (do 80%) učestalošću patologije među ženama u reproduktivnoj dobi i rizikom od razvoja patologije kod trudnica i 
novorođenčadi. Cilj: Proučiti utjecaj magnezija i vitamina D u kompleksnoj terapiji trudnica s UCTD-om na tijek trudnoće, 
porođaja, stanja trudnica i novorođenčadi. Metode: Analizirane su 142 žene s manifestacijama UCTD tijekom trudnoće. 
Ovisno o režimu liječenja ispitanice su podijeljene u skupine: trudnice skupine 1 (n = 87) primljene u kontinuiranom načinu 
rada “Magne-B6” - 4 tablete/dan (192 mg), trudnice skupine 2 (n = 55) i dodatno Aquadetrim ”- 1000 IU/dan. Istraživanje je 
provedeno prema jedinstvenoj shemi. Rezultati: Utvrđeno je da uzimanje lijekova s magnezijem i vitaminom D kompenzira 
njihov nedostatak u tijelu trudnice s UCTD i smanjuje rizik od preeklampsije (p = 0,031) kao i sindrom zastoja rasta fetusa 
(p = 0,048), doprinosi bržoj fi ziološkoj prilagodbi novorođenčeta u ranom postporođajnom razdoblju (p <0,05), manja je 
morfofunkcijska nezrelost (p = 0,030) i smanjene su manifestacije konjugacijske žutice (p = 0,019). Zaključak: Uzimanje 
magnezija i vitamina D kompenzira njihov nedostatak u tijelu trudnice s UCTD-om što smanjuje rizik od komplikacija kod 
žene i novorođenčeta.
Ključne riječi: nediferencirana bolest vezivnog tkiva, vitamin D, magnezij, trudnoća, novorođenčad, opstetrijske i perinatalne 
 komplikacije, preeklampsija
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